Cellectis Competitors and Similar CompaniesClear all
Cellectis's competitors and similar companies include Polymun, Allogene Therapeutics, Cipla and UCB.
 Cellectis Cellectis is a clinical-stage biopharmaceutical company that develops cell and gene therapies. |  Polymun Polymun is a company specializing in contract development and manufacturing as well as creating liposomal formats of drugs for contract partners. |  Allogene Therapeutics Allogene Therapeutics is a clinical-stage biotechnology company developing allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer. |  Cipla Cipla is a pharmaceutical company focused on the development, manufacturing, and distribution of medications and healthcare products. |  UCB UCB is a company that provides biopharmaceutical research and development solutions for neurological and immunological conditions. | |
Founding Date | Founding Date 1999 | Founding Date 1992 | Founding Date 2018 | Founding Date 1935 | Founding Date 1928 |
Type | Type Public | Type Private | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Paris, FR HQ New York, US Raleigh, US | Locations Klosterneuburg, AT HQ | Locations South San Francisco, US HQ | Locations Mumbai, IN HQ Melbourne, AU Antwerpen, BE São Paulo, BR São Paulo, BR Unterhaching, DE Nairobi, KE see more | Locations Brussels, BE HQ Melbourne, AU Vienna, AT Braine L'alleud, BE Braine L'alleud, BE Leuven, BE São Paulo, BR see more |
Employees | Employees 216 | Employees 80 | Employees 2263% decrease | Employees 27,764 | Employees 9,052 |
Valuation ($) | Valuation ($) 189.4 m | Valuation ($) N/A | Valuation ($) 585.5 m | Valuation ($) N/A | Valuation ($) 34.3 b |
Financial | |||||
Revenue (est.) | Revenue (est.) $72.9m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) ₹277.1b (FY, 2026) | Revenue (est.) €7.4b (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods ₹95.5b (FY, 2026) | Cost of goods €1.4b (FY, 2025) |
Gross profit | Gross profit $80.2m (FY, 2025) | Gross profit N/A | Gross profit N/A | Gross profit ₹195b (FY, 2026) | Gross profit €7.2b (FY, 2025) |
Net income | Net income ($67.6m) (FY, 2025) | Net income N/A | Net income ($190.9m) (FY, 2025) | Net income ₹38.7b (FY, 2026) | Net income €1.6b (FY, 2025) |
Funding | |||||
Total funding raised | Total funding raised $ 3.2m | Total funding raised N/A | Total funding raised $ 532m | Total funding raised N/A | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Polymun
HQ
Klosterneuburg, AT
Employees
80
Polymun is a company specializing in contract development and manufacturing as well as creating liposomal formats of drugs for contract partners.
View companyAllogene Therapeutics
HQ
South San Francisco, US
Employees
226↓ 3% decrease
Allogene Therapeutics is a clinical-stage biotechnology company developing allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer.
View companyCipla
HQ
Mumbai, IN
Employees
27,764
Cipla is a pharmaceutical company focused on the development, manufacturing, and distribution of medications and healthcare products.
View companyUCB
HQ
Brussels, BE
Employees
9,052
UCB is a company that provides biopharmaceutical research and development solutions for neurological and immunological conditions.
View company